Federal regulators are formally warning drug companies that fall behind on required pediatric studies, using a legal tool designed to push sponsors to test medicines in children and update labeling when evidence is available.
Under section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act, the U.S. Food and Drug Administration (FDA) issues what it calls Pediatric Research Equity Act (PREA) Non‑Compliance Letters to sponsors that miss key obligations. The agency describes the process and its legal basis on an FDA.gov page dedicated to these letters.
According to that FDA material, the letters go to sponsors that have failed to submit their required pediatric assessments by the final due date and have not obtained a deferral or an extension of a deferral. The notices are one of the clearest public signals that a company has not met its pediatric study commitments under PREA.
What the law requires
The Pediatric Research Equity Act, incorporated into section 505B of the Federal Food, Drug, and Cosmetic Act, allows the FDA to require pediatric studies for certain drugs and biologics. These studies, known as pediatric assessments, are intended to determine how a medicine works in children, what doses are appropriate, and what safety issues may be specific to younger patients.
As the FDA explains in its description of Non‑Compliance Letters, sponsors are generally expected to:
- Conduct the pediatric studies the agency requires under PREA.
- Submit the resulting pediatric assessments to the FDA by an agreed‑upon final due date.
- If they cannot meet that deadline, seek and obtain a deferral or an extension of a deferral from the agency.
Section 505B(d)(1) specifically addresses what happens when those expectations are not met. If a sponsor does not submit the required pediatric assessment by the final due date and has not secured a deferral or deferral extension, the statute requires the FDA to send a Non‑Compliance Letter.
When a Non‑Compliance Letter is triggered
The FDA’s public explanation of the process makes clear that the trigger for a PREA Non‑Compliance Letter is narrow and procedural: it is tied to missed deadlines and the absence of an approved delay.
In practical terms, a letter is sent when three conditions, as described by the agency, are all present:
- A pediatric assessment is required under PREA for a particular product.
- A final due date for that assessment has passed.
- The sponsor has neither submitted the assessment nor obtained a deferral or deferral extension.
The agency’s materials emphasize that the obligation to send a Non‑Compliance Letter in these circumstances comes directly from section 505B(d)(1). The letter itself is the formal notification that the sponsor is out of compliance with its PREA obligations for that product.
Why the letters matter for patients and providers
Although the FDA’s description focuses on the legal framework, the existence of Non‑Compliance Letters has practical implications for how medicines are used in children.
Pediatric assessments can lead to updates in product labeling, including dosing information, safety warnings, and indications that are specific to pediatric age groups. When those assessments are delayed, the information available to pediatricians and families may lag behind the evidence regulators expect to see.
By publicly documenting when sponsors have not met their pediatric study deadlines, the Non‑Compliance Letters serve several functions, as reflected in the FDA’s explanation of the program:
- Regulatory pressure on sponsors. The letters formally record that a company has not met a statutory requirement tied to pediatric data.
- Transparency for clinicians and the public. The existence of a Non‑Compliance Letter signals that required pediatric information has not yet been submitted by the sponsor.
- Accountability for pediatric commitments. Because PREA obligations are linked to specific products, the letters connect missed deadlines to particular medicines.
The FDA’s own framing of the letters underscores their role as a compliance tool rather than a scientific assessment of the product’s benefits and risks. A Non‑Compliance Letter does not, by itself, state that a drug is unsafe or ineffective in children; it indicates that the required pediatric assessment has not been provided on time and without an approved delay.
How Non‑Compliance Letters fit into the broader PREA process
Within the PREA framework described on FDA.gov, Non‑Compliance Letters appear at the enforcement end of a longer process that starts when a product is first evaluated for pediatric requirements.
According to the agency’s description, that process typically includes:
- Determining whether PREA applies to a given drug or biologic.
- Specifying what pediatric studies are required and setting timelines for completion.
- Allowing sponsors to request deferrals (delays in submitting pediatric data) or waivers (when studies are not feasible or appropriate), subject to FDA review.
The Non‑Compliance Letter mechanism comes into play only after those steps, when a sponsor neither meets the original due date nor secures a change to it through a deferral or deferral extension. The letter does not replace other regulatory tools the FDA may have, but it is specifically mandated by section 505B(d)(1) for this type of missed pediatric deadline.
The FDA’s public information does not, in this description, detail every potential consequence that could follow a Non‑Compliance Letter, such as additional enforcement actions or impacts on approvals. Instead, the focus is on the statutory requirement to issue the letter when the conditions in section 505B(d)(1) are met.
What to watch
The FDA’s use of PREA Non‑Compliance Letters under section 505B(d)(1) highlights how pediatric obligations are enforced once a drug or biologic is on the market. For families and clinicians, the presence of such a letter on a product indicates that required pediatric data have not been submitted on schedule and that no formal delay has been granted.
Because the current public description on FDA.gov is the primary available account of how these letters function, independent corroboration of specific outcomes associated with individual letters is limited and should be monitored as additional reporting emerges.
For now, the agency’s own explanation makes one point clear: when sponsors miss pediatric assessment deadlines without an approved deferral or extension, the FDA is required by law to put that non‑compliance in writing, creating a visible record tied to the medicines children may ultimately receive.
